HCPCS
J0596
1 unit = 10 IU
Phase 1
Identify what you're billing
Lock in unit conversion, the 4,200 IU cap, and rabbit-allergy screening before billing.
HAE C1-INH / mAb class comparison Reviewed May 2026
Five products, five HCPCS codes. Ruconest is the only recombinant; the only one with a rabbit-allergy contraindication; the cheapest per IU.
| Product | HCPCS | Class / origin | Route | Use | Q2 2026 ASP+6% |
|---|---|---|---|---|---|
| Ruconest (conestat alfa) | J0596 |
C1-INH recombinant (rabbit milk) | IV ~5 min | Acute / on-demand | $36.675 / 10 IU = ~$3.67/IU |
| Berinert (C1-INH human) | J0597 |
C1-INH plasma-derived | IV ~10 min | Acute / on-demand | ~$7.61 / IU |
| Cinryze (C1-INH human) | J0598 |
C1-INH plasma-derived | IV ~10 min | Prophylaxis (q3-4 days) | ~$6.55 / IU |
| Haegarda (C1-INH human SC) | J0599 |
C1-INH plasma-derived | SC | Prophylaxis (twice weekly) | ~$5.50 / IU |
| Takhzyro (lanadelumab) | J0593 |
Anti-kallikrein mAb | SC | Prophylaxis (q2w) | per mg (different unit) |
Ruconest's two structural differentiators: (1) materially cheaper per IU than plasma-derived
on-demand alternatives (Berinert), with the trade-off of (2) a rabbit-allergy contraindication
absent from any other HAE product. Pre-treatment rabbit-allergy screening is mandatory documentation.
Distinct billing codes — do not interchange. Each HAE product has its own permanent J-code.
J0596 (Ruconest) and J0597 (Berinert) are NOT substitutable on a claim. Verify NDC matches HCPCS at submission.
Recombinant vs plasma-derived — what changes for billing Reviewed May 2026
Origin matters for cost, contraindications, and supply.
Recombinant (Ruconest)
- Source: human C1-INH gene expressed in milk of transgenic rabbits
- No human plasma exposure — no risk of plasma-borne pathogen transmission
- Lower per-IU cost at scale (recombinant manufacturing economics)
- Unique contraindication: rabbit-protein allergy (residual rabbit milk proteins)
- Half-life ~3 hours (shorter than plasma-derived products)
Plasma-derived (Berinert, Cinryze, Haegarda)
- Source: pooled human plasma; viral inactivation processing
- No rabbit-allergy concerns
- Half-life ~30 hours — supports prophylaxis dosing intervals
- Subject to plasma supply constraints
- Higher per-IU ASP than Ruconest
Why the cost gap matters for utilization management: per-IU economics favor Ruconest for
on-demand acute attacks in patients without rabbit allergy. Some payers explicitly steer to Ruconest
first-line for acute treatment subject to allergy clearance. Verify per-payer.
Dosing & unit math FDA label most recent rev
From FDA prescribing information for Ruconest (BLA 125429).
Adolescent & adult dosing
- 50 IU/kg IV at the first sign of HAE attack
- Maximum dose: 4,200 IU (NOT weight-uncapped)
- For patients >84 kg: still 4,200 IU max — do not exceed cap
- If attack symptoms persist, a second dose may be administered (within 24 hours, max 4,200 IU)
- Slow IV injection over ~5 minutes (push, not drip)
The unit conversion (#1 biller error)
1 unit J0596 = 10 IU Ruconest. Always divide IU administered by 10 to get billable units.
Submitting raw IU as units inflates the claim 10× and triggers immediate audit and recoupment.
| Patient weight | 50 IU/kg dose | IU billed | J0596 units (÷10) | Vials used |
|---|---|---|---|---|
| 40 kg | 2,000 IU | 2,000 IU | 200 units | 1 vial (waste 100 IU) |
| 50 kg | 2,500 IU | 2,500 IU | 250 units | 2 vials (waste 1,700 IU) |
| 60 kg | 3,000 IU | 3,000 IU | 300 units | 2 vials (waste 1,200 IU) |
| 70 kg | 3,500 IU | 3,500 IU | 350 units | 2 vials (waste 700 IU) |
| 80 kg | 4,000 IU | 4,000 IU | 400 units | 2 vials (waste 200 IU) |
| 84+ kg (capped) | 4,200 IU (max) | 4,200 IU | 420 units | 2 vials (no waste) |
Worked example — 70 kg adult, single acute attack
# Dose calculation
Weight: 70 kg · Dose: 50 IU/kg = 3,500 IU
Vials needed: 2 × 2,100 IU = 4,200 IU available
Administered: 3,500 IU · Discarded: 700 IU
# Billing translation (1 unit = 10 IU)
J0596 units administered: 350 — with JW for waste
J0596 units discarded (JW line): 70
Admin: 96365 (therapeutic IV, ~5 min push fits within 1-hour window)
# Q2 2026 reimbursement (ASP+6%)
Drug administered: 350 × $36.675 = $12,836.25
Drug waste (JW): 70 × $36.675 = $2,567.25
Total reimbursed: $15,403.50 (drug only, before sequestration)
Weight: 70 kg · Dose: 50 IU/kg = 3,500 IU
Vials needed: 2 × 2,100 IU = 4,200 IU available
Administered: 3,500 IU · Discarded: 700 IU
# Billing translation (1 unit = 10 IU)
J0596 units administered: 350 — with JW for waste
J0596 units discarded (JW line): 70
Admin: 96365 (therapeutic IV, ~5 min push fits within 1-hour window)
# Q2 2026 reimbursement (ASP+6%)
Drug administered: 350 × $36.675 = $12,836.25
Drug waste (JW): 70 × $36.675 = $2,567.25
Total reimbursed: $15,403.50 (drug only, before sequestration)
Reconstitution
- 2,100 IU lyophilized vial + 14 mL sterile water for injection → 150 IU/mL solution
- Swirl gently — do not shake
- Use within 8 hours of reconstitution; keep at room temperature post-reconstitution
NDC reference FDA NDC Directory verified May 2026
| NDC (10/11-digit) | Package | Use |
|---|---|---|
42227-081-01 / 42227-0081-01 |
2,100 IU lyophilized single-dose vial — 1 vial per carton, supplied with 14 mL sterile water | Standard packaging; for adult dose use 1–2 vials per attack |
Use the 11-digit padded NDC on claims. CMS-1500 box 24A shaded area requires N4 qualifier
+ 11-digit NDC + unit-of-measure (UN1 for vial, ML if reporting volume) + quantity. Many MACs still reject
10-digit-format NDCs.
Rabbit-allergy contraindication — mandatory pre-treatment screening FDA boxed contraindication
Unique to Ruconest. Document the screening before the first dose or expect denial / safety event.
Contraindication: Ruconest is contraindicated in patients with known or suspected
allergy to rabbits or rabbit-derived products. The recombinant protein is harvested from the milk of
transgenic rabbits and contains trace residual rabbit proteins capable of triggering anaphylaxis.
Pre-treatment workflow
- History: ask about prior rabbit exposure (pets, lab animals, hunting), any reaction symptoms
- If any positive history or uncertain: refer to allergy/immunology for serum-specific IgE testing or supervised challenge
- Negative-screen documentation goes in the medical record before the first dose
- If positive: use plasma-derived alternative (Berinert J0597 for on-demand) or Takhzyro J0593 for prophylaxis
Hypersensitivity monitoring
- Monitor patients during and immediately after IV administration
- Have anaphylaxis treatment available on-site (epinephrine, IV access, airway)
- Discontinue if hypersensitivity occurs — switch to plasma-derived alternative
Documentation tip: Payers increasingly require explicit chart entries confirming
rabbit-allergy clearance before approving J0596 PA. A note like "rabbit-protein allergy negative by
history; serum-specific IgE not indicated" satisfies most payers.
Phase 2
Code the claim
96365 admin (non-chemo IV), JZ for whole-vial use, JW for partial-vial waste.
Administration codes CPT verified May 2026
Ruconest is a non-chemotherapy IV biologic — therapeutic IV admin codes apply.
| Code | Description | When to use |
|---|---|---|
96365 |
Therapeutic, prophylactic, or diagnostic IV infusion; up to 1 hour, single or initial substance/drug | Primary admin code for Ruconest. ~5-min slow IV push fits within 1-hour window. |
96374 |
Therapeutic IV push, single or initial substance | Some MACs prefer 96374 for ~5-min IV push delivery. Verify regional MAC guidance; either is defensible. |
96413 |
Chemotherapy IV admin | NOT appropriate. Ruconest is not classified under CPT chemo admin. |
S9329 + 99601 / 99602 |
Home infusion bundles + per-visit nursing | Home administration: trained patient/caregiver self-administration is approved post-training. Use S-codes only when home-infusion vendor is involved. |
Home self-administration
Home self-administration of Ruconest is FDA-approved after training, but uptake is lower than for Berinert because the IV reconstitution + 5-minute push workflow is more involved than Berinert's slower drip. When home admin is used, document training completion and bill home-infusion supply codes (S9329) rather than facility 96365.
Why 96365, not 96413: Ruconest is a non-chemo therapeutic biologic. CPT chemotherapy
admin codes (96409–96425) are reserved for antineoplastics and complex monoclonal antibody regimens
per AMA classification. Misbilling 96413 will be flagged.
Modifiers CMS verified May 2026
JZ — whole-vial use, no waste
Effective July 1, 2023, CMS requires the JZ modifier on all single-dose container claims when no drug is discarded. Ruconest is supplied in 2,100 IU SDVs. JZ applies for patients dosed at exact multiples of 2,100 IU (e.g., 84+ kg patients receiving the 4,200 IU max from two whole vials with zero waste).
JW — partial-vial waste (very common with Ruconest)
Because Ruconest dosing is weight-based (50 IU/kg) but supplied only as fixed 2,100 IU vials, partial-vial waste is the rule, not the exception. A 60 kg patient needs 3,000 IU — which requires opening 2 vials (4,200 IU available) and discarding 1,200 IU. Bill the administered units on the primary line and the discarded units on a separate JW line.
Common error: forgetting the JW waste line. CMS audit-recoups this when the math doesn't
match vial counts. Always document weight, calculated dose, vials opened, and discarded volume in the
infusion note.
One of JZ or JW must appear on every J0596 claim
Per CMS's July 2023 single-dose container policy, every claim line for J0596 must carry either JZ (no waste) or JW (with waste). Missing either will trigger denial or rejection.
Modifier 25 — same-day E/M
Use modifier 25 on the E/M code when a significant, separately identifiable evaluation and management service is performed on the same day as the infusion (typical for HAE acute attack visits where the patient presents with new symptoms requiring assessment).
340B modifiers (JG, TB)
For 340B-acquired Ruconest, follow your MAC's current 340B modifier policy. Pharming's billing materials do not provide 340B-specific instructions.
ICD-10-CM FY2026 verified May 2026
| Code | Description | Use |
|---|---|---|
D84.1 | Defects in the complement system | Primary HAE Type I/II Dx code. Required by all major payers. |
T78.3XXA | Angioneurotic edema, initial encounter | Acute attack encounter; pair with D84.1 for HAE-specific cause |
T78.3XXD | Angioneurotic edema, subsequent encounter | Follow-up after acute attack management |
T78.3XXS | Angioneurotic edema, sequela | Late effects from prior attack |
Always pair D84.1 (HAE etiology) with T78.3XXA (acute attack) on acute-treatment claims.
Most payers require the combination to confirm both the underlying complement-deficiency diagnosis and
the acute attack indication for the on-demand product.
Site of care & place of service Verified May 2026
Acute HAE attacks are time-sensitive — site of care follows where the patient presents. Most payers accept ED, office, infusion center, and (for trained patients) home self-administration without prior site-of-care steering for on-demand acute treatment.
| Setting | POS | Claim form | Notes |
|---|---|---|---|
| Allergy/immunology office | 11 | CMS-1500 / 837P | Common for known HAE patients with attack-action plan |
| Ambulatory infusion suite | 49 | CMS-1500 / 837P | Acceptable |
| Emergency department | 23 | UB-04 / 837I | Common for first attack or severe presentations |
| Hospital outpatient | 22 | UB-04 / 837I | Acceptable for acute treatment |
| Patient home (self/caregiver) | 12 | CMS-1500 (with home-infusion bundle) | Approved post-training; uptake lower than Berinert |
On-demand pre-positioning: Most HAE patients keep Ruconest at home or carry it for
immediate use at attack onset. Specialty pharmacy ships under the medical benefit (buy-and-bill model
less common for on-demand HAE products). Verify dispensing pathway with the patient's specialty pharmacy.
Claim form field mapping Pharming 2026
From Pharming Patient Support coding & coverage materials.
| Information | CMS-1500 box | Notes |
|---|---|---|
| NPI | 17b | Rendering provider |
| NDC qualifier + 11-digit NDC + UoM + qty | 24A shaded area | N4 + 42227-0081-01 + UN1 + vials used |
| HCPCS J0596 + JZ or JW | 24D (drug line) | JW for partial-vial waste, JZ for whole-vial use |
| Drug units (administered) | 24G | IU administered ÷ 10 |
| Drug units waste (JW line) | 24G | IU discarded ÷ 10 — separate line item |
| CPT 96365 or 96374 (admin line) | 24D (admin line) | ~5-min IV push within 1-hour window |
| ICD-10 | 21 | D84.1 + T78.3XXA |
| PA number | 23 | Required by all major payers for HAE on-demand |
Phase 3
Get paid
PA + HAE Type I/II Dx + acute attack documentation + rabbit-allergy negative.
Payer policy snapshot Reviewed May 2026
All major payers require PA for HAE products. Specialist (allergy/immunology) prescription is typical.
| Payer | PA? | Key criteria | Notes |
|---|---|---|---|
| UnitedHealthcare HAE Coverage Policy / LCD |
Yes | HAE Type I or II diagnosis (D84.1 + complement testing), acute attack symptoms, rabbit-allergy negative documented, allergy/immunology prescriber typical | On-demand pre-positioning at home or with patient permitted |
| Aetna CPB / Medical Drug policy |
Yes | HAE Dx confirmed by C1-INH level/function or genetic testing; rabbit-allergy clearance; specialist Rx | Quantity limits on monthly attack frequency |
| BCBS plans Vary by plan |
Yes | Generally aligned with US HAEA / WAO-EAACI HAE guidelines | Plan-specific; some require step through plasma-derived for chronic on-demand patients |
| Medicare (MAC) | Generally no | FDA-labeled use under D84.1 + T78.3XXA; coverage per MAC LCDs for HAE biologics | No NCD specific to Ruconest |
Step therapy
Some payers require trial of a plasma-derived on-demand product (Berinert J0597) before approving Ruconest, while others steer toward Ruconest first-line on cost grounds (lower per-IU ASP). Verify per-payer; HAE step-therapy criteria are inconsistent across plans.
Specialty pharmacy
Several specialty pharmacies stock Ruconest under the medical benefit (buy-and-bill is less common than for in-clinic infusion drugs). Common dispensers include AcariaHealth, Optum Specialty, AllianceRx Walgreens Prime, and Accredo. Confirm dispensing channel as part of PA submission.
Medicare reimbursement CMS Q2 2026 (live)
Quarterly ASP from CMS Part B Drug Pricing File. Refreshes automatically each quarter.
Q2 2026 payment snapshot — J0596
Effective April 1 – June 30, 2026 · Based on 4Q25 ASP submissions
ASP + 6%
$36.675
per 10-IU unit (~$3.67/IU)
2,100 IU vial (210 units)
$7,701.75
single vial × ASP+6%
4,200 IU max dose (420 units)
$15,403.50
max single attack treatment
Cost vs plasma-derived: Ruconest at ~$3.67/IU is materially less expensive than Berinert
(~$7.61/IU on-demand) and Cinryze (~$6.55/IU prophylaxis). For a 70 kg patient with monthly acute
attacks, Ruconest year-1 (12 attacks × 3,500 IU) totals ~$154,000/year before sequestration vs
~$320,000/year for the same volume with Berinert.
Coverage
No NCD specific to Ruconest. Coverage falls under MAC LCDs for HAE biologics + the standard Part B biologic framework. All MACs cover J0596 for FDA-approved on-label HAE Type I/II acute attack treatment with appropriate ICD-10 documentation.
Code history
- J0596 — permanent code, "Injection, C1 esterase inhibitor (recombinant), Ruconest, 10 units"
Patient assistance — Pharming Patient Support / RuconestKey Pharming verified May 2026
- Pharming Patient Support / RuconestKey: 1-866-411-2848 — benefits investigation, prior authorization assistance, appeal support, dispensing coordination
- Ruconest Co-pay Program: commercial copay support; eligible commercially-insured patients (excludes Medicare, Medicaid, federal program patients)
- Pharming Patient Assistance Program: free product for uninsured / underinsured patients meeting income requirements
- Foundations: for Medicare patients, refer to PAN, HealthWell, NORD, US HAEA — verify open HAE funds quarterly
- Web: ruconest.com / pharming.com
Need to model what a specific HAE patient will actually pay after copay assistance, deductible,
coinsurance, and OOP max? Run a CareCost Estimate — J0596 pre-loaded.
Phase 4
Fix problems
Unit conversion error, missing rabbit-allergy clearance, missing JW waste line are the top three.
Common denials & how to fix them
| Denial reason | Common cause | Fix |
|---|---|---|
| Units billed 10× too high | Raw IU submitted as units (forgot 1 unit = 10 IU) | Resubmit with corrected units = IU ÷ 10. A 4,200 IU dose is 420 units, not 4,200. |
| Rabbit-allergy clearance not documented | PA submitted without explicit rabbit-protein allergy screening note | Add chart entry: "rabbit-protein allergy negative by history" or document allergy/immunology evaluation. |
| JW waste line missing | Partial-vial waste not reported on weight-based dose | Add JW line for discarded units (IU discarded ÷ 10). Common with non-84-kg-multiple weights. |
| JZ missing on whole-vial claim | Single-dose vial claim without JZ when no waste | Resubmit with JZ. Required since 7/1/2023 on every claim with no waste. |
| Indication denial: prophylaxis | Submitted for routine HAE prophylaxis (not approved) | Ruconest is on-demand only. Switch to Cinryze (J0598), Haegarda (J0599), or Takhzyro (J0593) for prophylaxis. |
| Wrong admin code (96413) | Chemo IV billed instead of therapeutic IV | Resubmit with 96365 or 96374. Ruconest is non-chemotherapy. |
| Step therapy through plasma-derived not met | Plan requires Berinert trial first | Document Berinert trial/failure or contraindication. Alternatively, submit medical necessity letter citing per-IU cost advantage of Ruconest. |
| Wrong NDC format | 10-digit NDC submitted instead of 11-digit padded | Use 11-digit format: 42227-0081-01. |
| Dose > 4,200 IU | Weight-uncapped 50 IU/kg dosing for >84 kg patient | Ruconest is capped at 4,200 IU (420 units) regardless of weight. Resubmit with capped dose. |
Frequently asked questions
What is the HCPCS code for Ruconest?
Ruconest (C1 esterase inhibitor recombinant, conestat alfa) is billed under HCPCS J0596
— "Injection, C1 esterase inhibitor (recombinant), Ruconest, 10 units." One billable unit equals
10 IU.
How many units do I bill for a 50 IU/kg Ruconest dose?
Divide total IU administered by 10. A 70 kg patient receives 50 IU/kg = 3,500 IU = 350 units of J0596. The maximum dose is 4,200 IU (= 420 units) regardless of patient weight, even for patients over 84 kg.
What administration CPT do I use for Ruconest?
CPT 96365 — therapeutic IV infusion, non-chemotherapy, up to 1 hour. Some MACs prefer
96374 for IV push. Ruconest is given as a slow IV push over ~5 minutes, well within either
code's time window. Do NOT bill 96413 (chemo admin).
Do I bill JZ or JW for Ruconest?
Both can apply. Use JZ for whole-vial use with no waste (typical at the 4,200 IU max dose, two whole vials). Use JW for the discarded portion when weight-based dosing produces partial-vial waste — which is common because Ruconest is supplied only as 2,100 IU vials. One of JZ or JW must be on every J0596 claim.
What is the Medicare reimbursement for J0596?
For Q2 2026, the Medicare Part B payment limit for J0596 is $36.675 per 10-IU unit (~$3.67/IU, ASP + 6%). The standard maximum 4,200 IU dose reimburses at approximately $15,403.50 per attack treatment.
Is Ruconest contraindicated in patients with rabbit allergies?
Yes — absolute contraindication. Ruconest is produced in the milk of transgenic rabbits, so any patient with known or suspected rabbit-protein allergy cannot receive it. Pre-treatment screening for rabbit allergy must be documented in the medical record before the first dose.
Is Ruconest indicated for HAE prophylaxis?
No. Ruconest is approved on-demand only — for treatment of acute angioedema attacks in adolescents and adults with HAE Type I or Type II. It is NOT indicated for routine prophylaxis. Use Cinryze (J0598, IV q3-4d), Haegarda (J0599, SC twice weekly), or Takhzyro (J0593, SC q2w) for prophylaxis.
How does Ruconest differ from Berinert and Cinryze?
Ruconest is recombinant C1-INH produced in transgenic rabbit milk. Berinert (J0597) and Cinryze (J0598) are plasma-derived from human donors. Ruconest is materially cheaper per IU (~$3.67/IU vs ~$7.61/IU for Berinert and ~$6.55/IU for Cinryze) but carries a rabbit-allergy contraindication absent from the plasma-derived products. All three are IV; only Ruconest and Berinert are on-demand acute treatments — Cinryze is FDA-approved for prophylaxis.
Reference
Sources & methodology
Every claim on this page is sourced. Methodology and review history below.
Source documents
- DailyMed — RUCONEST (C1 Esterase Inhibitor [Recombinant]) Prescribing Information
- Pharming — Ruconest HCP / patient site
- CMS — Medicare Part B Drug ASP Pricing File
- US Hereditary Angioedema Association (US HAEA)
- WAO/EAACI Guideline for the Management of Hereditary Angioedema (2021 update)
- SEER CanMED — HCPCS J0596 reference
- UnitedHealthcare — HAE coverage policy
- Aetna — CPB / Medical Drug policy for HAE products
- FDA National Drug Code Directory
About this page
We maintain this page as a living reference. Medicare ASP pricing is bound to our underlying CareCost data layer and refreshes automatically when CMS publishes new quarterly files. Coding and policy content is reviewed at least quarterly and updated whenever a source document changes.
Found an error? Email hello@carecostestimate.com.
Refresh cadence
| Element | Cadence | How it's refreshed |
|---|---|---|
| Medicare ASP pricing | Quarterly | Auto-bound to CareCost ASP layer; updates on CMS file release. |
| Payer policies (UHC, Aetna, BCBS) | Semi-annual | Manual review against published payer policy documents. |
| HCPCS / CPT / modifier rules | Annual | Reviewed against CMS HCPCS quarterly files and AMA CPT releases. |
| NDC, dosing, FDA label, contraindications | Event-driven | Tied to manufacturer document version + FDA label revision date. |
Reviewer
Pending SME review. This page is staff-authored from primary sources (FDA, CMS,
Pharming Patient Support, payer documents — all linked above). Editorial review in progress. Until that review is complete, treat this as a draft reference and verify
each cited source for high-stakes claims.
Change log
- — Initial publication. ASP data: Q2 2026. Manufacturer source: Pharming 2026 (RuconestKey patient support / FDA label most recent revision). Class context: Berinert (J0597), Cinryze (J0598), Haegarda (J0599), Takhzyro (J0593).
Methodology
Every claim on this page is sourced inline. Pricing reflects the current CMS Part B Drug ASP Pricing File. Payer policies are read directly from each payer's published medical/pharmacy policy documents. Indication and contraindication content is verified against the current FDA label revision. We do not paraphrase from billing-software vendor blogs.